Literature DB >> 21505306

Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

Olga Latinovic1, Nhut Le, Marvin Reitz, Ranajit Pal, Anthony DeVico, James S Foulke, Robert R Redfield, Alonso Heredia.   

Abstract

CCR5 blockers inhibit CCR5-tropic (R5) HIV-1, including strains resistant to other antiretrovirals. We demonstrate that the CCR5 antibody HGS004 and the CCR5 antagonist maraviroc have potent antiviral synergy against R5 HIV-1, translating into dose reductions of more than 10-fold for maraviroc and more than 150-fold for HGS004. These data, together with the high barrier of resistance to HGS004, suggest that combinations of maraviroc and HGS004 could provide effective preventive and therapeutic strategies against R5 HIV-1.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21505306      PMCID： PMC3748726          DOI： 10.1097/QAD.0b013e3283471edb

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  21 in total

Review 1.  HIV entry: new insights and implications for patient management.

Authors:  Amelia Hughes; Mark Nelson
Journal:  Curr Opin Infect Dis       Date:  2009-02       Impact factor: 4.915

2.  FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.

Authors: 
Journal:  AIDS Alert       Date:  2007-09

3.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

4.  Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Authors:  Jose D Murga; Michael Franti; Daniel C Pevear; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

5.  Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Olga Latinovic; Robert C Gallo; Gregory Melikyan; Marv Reitz; Nhut Le; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

6.  Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.

Authors:  Rama Kondru; Jun Zhang; Changhua Ji; Tara Mirzadegan; David Rotstein; Surya Sankuratri; Marianna Dioszegi
Journal:  Mol Pharmacol       Date:  2007-12-20       Impact factor: 4.436

7.  CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor.

Authors:  Changhua Ji; Jun Zhang; Marianna Dioszegi; Sophie Chiu; Eileen Rao; Andre Derosier; Nick Cammack; Michael Brandt; Surya Sankuratri
Journal:  Mol Pharmacol       Date:  2007-03-28       Impact factor: 4.436

8.  Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Authors:  Jeffrey M Jacobson; Michael S Saag; Melanie A Thompson; Margaret A Fischl; Ralph Liporace; Richard C Reichman; Robert R Redfield; Carl J Fichtenbaum; Barry S Zingman; Mahesh C Patel; Jose D Murga; Suzanne M Pemrick; Paul D'Ambrosio; Marti Michael; Hans Kroger; Hieu Ly; Yakov Rotshteyn; Robert Buice; Stephen A Morris; Joseph J Stavola; Paul J Maddon; Alton B Kremer; William C Olson
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

9.  Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.

Authors:  Jacob Lalezari; Gopal K Yadavalli; Michael Para; Gary Richmond; Edwin Dejesus; Stephen J Brown; Wendy Cai; Cecil Chen; John Zhong; Lu Anne Novello; Michael M Lederman; G Mani Subramanian
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

10.  Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.

Authors:  Pavel Pugach; Neelanjana Ray; Per Johan Klasse; Thomas J Ketas; Elizabeth Michael; Robert W Doms; Benhur Lee; John P Moore
Journal:  Virology       Date:  2009-03-20       Impact factor: 3.616
View more
  5 in total

1.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

Review 2.  CCR5 antagonism in HIV infection: current concepts and future opportunities.

Authors:  Timothy J Wilkin; Roy M Gulick
Journal:  Annu Rev Med       Date:  2011-10-27       Impact factor: 13.739

3.  Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.

Authors:  Olga Latinovic; Kate Schneider; Henryk Szmacinski; Joseph R Lakowicz; Alonso Heredia; Robert R Redfield
Journal:  Antiviral Res       Date:  2014-10-24       Impact factor: 5.970

4.  Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies.

Authors:  Matthew Weichseldorfer; Yutaka Tagaya; Marvin Reitz; Anthony L DeVico; Olga S Latinovic
Journal:  J Transl Med       Date:  2022-01-24       Impact factor: 5.531

Review 5.  Maraviroc: a review of its use in HIV infection and beyond.

Authors:  Shawna M Woollard; Georgette D Kanmogne
Journal:  Drug Des Devel Ther       Date:  2015-10-01       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.